Although the effect of antihypertensive drugs on COVID-19 patients with hypertension is controversial, the upregulation of ACE2 by ACE-inhibitors was linked to a dampened hyperinflammation and increased intrinsic antiviral responses of the cell in hypertensive COVID-19 patients [21]. Here, ACE is linked to COVID-19.